Track topics on Twitter Track topics that are important to you
RUXIENCE is a monoclonal antibody (mAb) for the treatment of non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA),
The post Pfizer receives positive CHMP opinion for oncology biosimilar RUXIENCE appeared first on Pharmaceutical Business review.
Original Article: Pfizer receives positive CHMP opinion for oncology biosimilar RUXIENCENEXT ARTICLE
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...